Printer Friendly

ISIS PHARMACEUTICALS DISCOVERS NEW BINDING TECHNIQUE

 ISIS PHARMACEUTICALS DISCOVERS NEW BINDING TECHNIQUE
 CARLSBAD, Calif., Aug. 31 /PRNewswire/ -- Isis Pharmaceuticals, Inc.


(NASDAQ: ISIP) has discovered a new method of binding oligonucleotides to RNA, as published in a recent issue of Science, volume 257.
 The most important regions of viral or cellular RNA are often highly structured and difficult to bind with antisense oligonucleotides. The Science report describes a new approach, known as pseudo-half-knot formation, in the design of antisense oligonucleotides to target these important structured regions. "Structured regions of RNA represent important targets for antisense drugs, the study of which will better enable us to design such drugs," said Dr. Christopher Mirabelli, senior vice president.
 Isis has demonstrated the utility of the technique by targeting one of the key regulatory RNA regions of HIV. It was shown that by binding to the HIV RNA using the pseudo-half-knot formation, the viral regulatory protein was displaced from its natural binding site. Isis has filed patent applications on this technique of drug discovery.
 Isis Pharmaceuticals, Inc., based in northern San Diego County, is engaged in the discovery and development of novel therapeutic products based on antisense oligonucleotides. Isis recently completed its initial Phase I human clinical trials on a new drug, the first antisense drug to be administered to humans, to treat human papillomavirus.
 -0- 8/31/92
 /CONTACT: Christopher Mirabelli, Ph.D., of Isis Pharmaceuticals, Inc., 619-931-9200, or Anthony J. Russo, of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
 (ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:


TS-LR -- NY011 -- 4815 08/31/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1992
Words:259
Previous Article:VISA IS NOT ENTITLED TO STOP CREDIT UNION'S NEW 'MONEYPLUS' CARD
Next Article:WORLDWIDE FOREST PRODUCTS WINS SUPPLY CONTRACT FOR DALLAS LIGHT RAIL SYSTEM
Topics:


Related Articles
ISIS RECEIVES FDA APPROVAL TO BEGIN CLINICAL TRIALS ON ANTISENSE HPV DRUG
ISIS PHARMACEUTICALS ACQUIRES RIGHTS TO 'PEPTIDE NUCLEIC ACID' TECHNOLOGY
Ibis Therapeutics, a Division of Isis Pharmaceuticals, Creates New Method to Discover RNA-Binding Drugs.
Isis Pharmaceuticals Broadens Licensing of Third-Generation Antisense Chemistry to Pantheco A/S for $1.1 Million License Fee.
Isis Pharmaceuticals' Ibis Therapeutics Division Wins R&D 100 Award.
Isis Pharmaceuticals enters into agreement with Pfizer.
Isis license functional genomics patents to atugen.
Antisense Therapeutics Limited and Isis Pharmaceuticals Initiate Phase I Trial of Antisense Drug for Multiple Sclerosis.
Isis Pharmaceuticals and Ercole Biotech Initiate Collaboration to Create Antisense Drugs Which Control Alternative Splicing.
Isis Gains Full Ownership of Orasense(TM) and HepaSense(TM) Subsidiaries and Eliminates Future Royalty Payments to Elan.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters